CASI Pharmaceuticals Loses China Import License for FOLOTYN®, Ceases Sales
CASI sits 31% above its 52-week low of $0.75.
Summary
CASI Pharmaceuticals announced that China's NMPA did not approve the renewal of the Import Drug Registration License for FOLOTYN®, leading to the cessation of its sales in China.
Key Events · Product Development and Regulatory · CASI
-
FOLOTYN® Import License Not Renewed
The Chinese National Medical Products Administration (NMPA) formally denied CASI Pharmaceuticals' application to renew the Import Drug Registration License for FOLOTYN®.
-
Cessation of Sales in China
Following the non-renewal, the company has ceased all sales of FOLOTYN® in China, a measure previously initiated after the license's expiration.
-
Impact on Revenue Stream
The decision permanently removes a commercial product from CASI's revenue stream in the Chinese market.
Analysis · CASI · Life Sciences
This 6-K filing confirms a significant setback for CASI Pharmaceuticals, as the formal denial of the FOLOTYN® import license renewal in China means a permanent loss of a commercial revenue stream in that market. While the company had previously ceased sales following the license's expiration, this official non-approval solidifies the long-term impact. For a clinical-stage biopharmaceutical company with a relatively small market capitalization, the loss of any commercial product's sales can materially affect its financial outlook and ability to fund ongoing drug development. Investors should monitor future financial reports for the full impact of this loss on the company's revenue and cash flow.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CASI was trading at $0.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.5M. The 52-week trading range was $0.75 to $3.09. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.